Join the Class Action Against Capricor Therapeutics: Investors Alert

Join the Class Action Against Capricor Therapeutics

Levi & Korsinsky, LLP is reaching out to investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding a significant class action lawsuit aimed at recovering losses resulting from alleged securities fraud. This action pertains to events that occurred from October 9, 2024, to July 10, 2025.

Background of the Case

The lawsuit emerges in the wake of claims that Capricor, which focuses on developing innovative cell therapies to treat serious medical conditions, misrepresented crucial information about its lead therapy drug, deramiocel. This drug is intended for treating Duchenne muscular dystrophy (DMD), a severe form of muscular dystrophy. Although initial reports suggested a positive trajectory for Capricor’s applications to the U.S. Food and Drug Administration (FDA), subsequent developments revealed a much darker narrative.

During the lawsuit period, Capricor promised investors that it would secure a Biologics License Application (BLA) from the FDA for deramiocel. Simultaneously, these assurances were possibly undermined by misleading statements and the concealment of critical information regarding the drug’s safety and efficacy as gathered from its Phase 2 HOPE-2 trial. On July 11, 2025, Capricor officially announced that they had received a Complete Response Letter (CRL) from the FDA, effectively denying their BLA application. The FDA cited a lack of substantial evidence of the drug's effectiveness needing further clinical data.

Impact on Investors

This news had immediate repercussions: Capricor’s stock price plummeted from $11.40 to $7.64 per share in a single day. Such dramatic stock movements raise concerns for investors who may have made decisions based on the misleading information disseminated by Capricor management.

If you were an investor during this timeframe and believe you experienced financial loss due to these practices, you may be eligible to join the class action suit. Financial restitution is crucial in these scenarios, especially as the fallout impacts investor confidence and market integrity.

Important Dates and Information

The deadline for filing claims is fast approaching—September 15, 2025—so prompt action is necessary to assert your rights as an affected investor. Enlistment as a lead plaintiff is not a requirement for receiving compensation. Whether or not you choose to take on this role, you may still participate and share in the recovery of losses without any out-of-pocket costs.

Levi & Korsinsky boasts two decades of experience in securing compensation for investors adversely affected by securities fraud. The firm has garnered a reputation for pioneering complex securities litigation and boasts a team of over 70 professionals committed to serving its clients effectively.

If you wish to learn more about this class action suit or need assistance, do not hesitate to reach out to the legal team. They can be contacted via email at [email protected] or by phone at (212) 363-7500.

Moreover, attending to this lawsuit can ensure that transparency and accountability are upheld in the management of public companies, which ultimately benefits the investing community as a whole. As investors, it is essential to remain vigilant and proactive in protecting your interests.

Conclusion

The journey ahead for Capricor Therapeutics remains uncertain, but what is clear is the demand for justice and honesty in the corporate environment. By participating in this class action suit, affected investors not only stand a chance to recover their losses but also send a message that transparency and ethical conduct are non-negotiable in the business world.

For more insights, please visit the Levi & Korsinsky website or directly access their secure class action form.
Join the Class Action